282 related articles for article (PubMed ID: 26012156)
1. [Liver damage caused by atorvastatin and cyclosporine in patients with renal transplant].
Ivandić E; Bašić-Jukić N
Acta Med Croatica; 2014 Apr; 68(2):175-8. PubMed ID: 26012156
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
4. Modifying cyclosporine associated renal allograft dysfunction.
Mohapatra N; Vanikar AV; Patel RD; Trivedi HL
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):770-4. PubMed ID: 19736471
[TBL] [Abstract][Full Text] [Related]
5. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
6. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.
Maltz HC; Balog DL; Cheigh JS
Ann Pharmacother; 1999 Nov; 33(11):1176-9. PubMed ID: 10573315
[TBL] [Abstract][Full Text] [Related]
8. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
9. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
[TBL] [Abstract][Full Text] [Related]
10. Is cyclosporine withdrawal a therapeutic option in renal transplant recipients with chronic allograft dysfunction?
Ducloux D
Minerva Urol Nefrol; 2003 Mar; 55(1):81-9. PubMed ID: 12773969
[TBL] [Abstract][Full Text] [Related]
11. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
12. Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study.
Ponticelli C; Salvadori M; Scolari MP; Citterio F; Rigotti P; Veneziano A; Bartezaghi M;
Transplantation; 2011 May; 91(10):e72-3. PubMed ID: 21540717
[No Abstract] [Full Text] [Related]
13. Immunosuppression in live-related donor renal transplantation.
Iman A; Rao M; Juneja R; Jacob CK
Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
[TBL] [Abstract][Full Text] [Related]
14. Rhabdomyolysis triggered by cytomegalovirus infection in a heart transplant patient on concomitant cyclosporine and atorvastatin therapy.
Wong WM; Wai-Hung Shek T; Chan KH; Chau E; Lai KC
J Gastroenterol Hepatol; 2004 Aug; 19(8):952-3. PubMed ID: 15242511
[No Abstract] [Full Text] [Related]
15. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
16. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
[TBL] [Abstract][Full Text] [Related]
17. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits.
Etienne I; Toupance O; Bénichou J; Thierry A; Al Najjar A; Hurault de Ligny B; Le Meur Y; Westeel PF; Marquet P; François A; Hellot MF; Godin M
Nephrol Dial Transplant; 2010 Sep; 25(9):3096-106. PubMed ID: 20299336
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
20. Conversion to sirolimus in kidney transplant recipients: a single-center study.
Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
